The endoplasmic reticulum (ER) is central to an array of cellular processes, including protein translation and modification (Schwarz and Blower, 2016) , lipogenesis (Fagone and Jackowski, 2009) and Ca 2 + homeostasis (Berridge et al., 2003) ; the disturbance of such functions is implicated in a wide range of disease processes. Here, we briefly summarize aspects of ER stress associated with neurodegenerative processes.
Ca 2 + homeostasis
The ER (in concert with mitochondria) is the cellular organelle responsible for Ca 2 + homeostasis and maintains a high Ca 2 + gradient (0.1 mmol/l ER lumen vs. 10 nM cytoplasmic; Moore et al., 1975) . This gradient is crucial particularly for excitable cells such as neurons as it forms the basis for intracellular and intercellular communication, and must be maintained despite the high associated energy demand. ER stores are regulated by the sarco/endoplasmic Ca 2 + ATPase pump (SERCA ATPase), which scavenges passive Ca 2 + leaks and recaptures Ca 2 + released by inositol triphosphate (IP 3 ) signalling, or through Ca 2 + -induced Ca 2 + release because of ryanodine receptor (RyR) stimulation (Berridge et al., 2003) .
Both ionotropic and metabotropic signalling can trigger Ca 2 + release from ER stores, which in turn causes extracellular Ca 2 + influx through the activation of storeoperated Ca 2 + channels (SOCC: Koss et al., 2009 Koss et al., , 2013 , ensuring refilling of ER stores, strengthening Ca 2 + -dependent signalling as well as activating distinct signalling pathways (Bobe et al., 2011; Zou et al., 2011; Selvaraj et al., 2012) . The importance of Ca 2 + homeostasis and excitotoxicity in neurodegenerative diseases has been acknowledged for many years; respective reviews on the topic have been published previously (see e.g. Berridge, 2010) .
Protein folding
The ER is the cellular centre for post-translational modification of newly synthesized proteins leading to the adoption of the correct tertiary structure. These mRNA sequences containing an ER recognition sequence encode proteins destined for either membrane integration or secretion, and contain a sequence recognition particle. The sequence recognition particle-guided translocation process feeds polypetides into the ER through a highly conserved heterotrimeric transmembrane protein channel translocon complex. Once inside, proteins undergo sequential post-translational modifications by for example, N-linked glycosylation, signal peptide cleavage, disulphide bond formation, proisomerization and oligomerization, each of which prompt, facilitate and stabilize proper protein folding. Critical to this process are numerous ER-resident protein chaperones, including members of the heat-shock protein (HSP) family, binding immunoglobulin protein (BIP) and glucose-regulated protein 94 (GRP94), as well as carbohydrate-selective chaperones such as calnexin and calreticulin (Schwarz and Blower, 2016) . Many of these chaperones are multifaceted, that is they carry out a variety of functions dependent on their interaction with adaptor proteins and the hydrolysis of ATP. For example, the protein-binding chaperone BIP requires nucleotide exchange factors such as Sil1 to regulate activitydependent substrate binding, whereas the association of endoplasmic reticulum J-domain protein (ERDJ) family members assists in localizing a variety of different substrates and thus exerts a degree of functional control. Such functions include the association of BIP with the translocon pore that recruits emerging polypeptides into the ER lumen, while also preventing ionic flow mediated by ERDJ1/2. In addition, the binding of unfolded proteins through ERDJ 3/6 and ERDJ 4/5 promotes binding of BIP to misfolded proteins and hence their subsequent degradation (Braakman and Hebert, 2013) . Only successfully chaperoned proteins are correctly presented for enzymatic modification and are ultimately available for transport to the Golgi apparatus.
Lipid biosynthesis
In concert with its roles in protein translation, the ER is the main site for lipid synthesis. High levels of glycerol-3-phosphate, O-aclytransferase and 1-acyl-sn-glycerol-3-phosphate O-acyltransferase, needed for the production of diacylglycerol phosphate, are present in the ER, alongside phosphatidic acid phosphatase enzymes, which convert diacyl-glycerol phosphate into diacylglycerol, the basis of all phospholipids. As such, the ER is the primary site for the production of most gylcerophospholipids, phosphatidylcholine and phosphatidylethanolamine, and also the storage of lipids in the form of triacylglycerol (Fagone and Jackowski, 2009 ). In contrast to the selfcontained production of gylcerophospholipids, the production of ceramide-containing sphingolipids is only initiated in the ER, which generates ceramides before trafficking to the Golgi apparatus, where sphingolipid synthesis is completed (Futerman and Riezman, 2005) .
Cross-talk between endoplasmic reticulum functions
A number of studies have reported a high degree of interdependence of ER functions: many protein chaperones that ensure proper protein folding, such as calrecticulin and calnexin, not only bind Ca 2 + , thus regulating both basal ER Ca 2 + and releasable Ca 2 + , but also limit SOCC activation (Fasolato et al., 1998) . Reciprocally, ER Ca 2 + oscillations modulate chaperone interactions with target proteins, which enable protein folding (Corbett et al., 1999) . Similarly balanced lipogenesis, which requires properly folded enzymes, is essential for SERCA ATPase modulation. Moreover, lipogenesis itself is regulated by ER luminal Ca 2 + (Fu et al., 2011) . This complementary balance of ER functionality and integrity is exemplified by the three principal means of inducing ER stress: tunicamycin, an inhibitor of N-link protein glycosylation (Agouni et al., 2011; Bassik and Kampmann, 2011) , thapisgargin, an irreversible inhibitor of the SERCA ATPase pump that induces ER Ca 2 + store depletion (Rogers et al., 1995; Koss et al., 2009 Koss et al., , 2013 , and palmitic acid, a saturated fatty acid that integrates into the ER membrane and causes a stress response independent of luminal protein folding (Volmer et al., 2013) .
The interdependence between ER regulatory pathways has wide-ranging implications as modifications or disruptions of one aspect have consequences on others. During ageing, essential protein chaperones such as calnexin and BIP (Brown and Naidoo, 2012) , together with SOCC (Vanterpool et al., 2005; Zhao et al., 2008; Brotto, 2011) and SERCA ATPase activity (Toescu and Verkhratsky, 2000; Puzianowska-Kuznicka and Kuznicki, 2009) , are downregulated, lowering ER Ca 2 + levels while increasing cytoplasmic Ca 2 + levels, thus priming the aged ER for dysfunction. This predisposition of ER to malfunction may be further exacerbated by numerous environmental stresses, such as toxic metals, infections, thermal stress and hypoxia (Kitamura, 2013) , and shows obvious links between neurodegenerative disease and metabolic conditions, such as type 2 diabetes and obesity (Chakrabarti et al., 2011) .
The unfolded protein response
During impaired ER function, the unfolded protein response (UPR) cascade is activated, initially as a physiological adaptive response to ER stress, which is initiated when the demand for protein translation exceeds the protein-folding capacity of the ER, and hence is caused either by inefficiencies in the ER machinery or by excessive protein demand. Errors within the folding process lead to an accumulation of mis/unfolded proteins, resulting in the sequestration of BIP. This removes the inhibitory influence of the chaperone over key ERresident initiators of UPR, which in turn activates the stress response.
An adaptive UPR promotes cell survival by three convergent pathways (Fig. 1 ) that lead to the following:
(1) The inhibition of general protein synthesis, promoting only the translation of key stress genes, by protein kinase double-stranded RNA-dependent (PKR)-like ER kinase (PERK)-mediated phosphorylation of eukaryotic initiation factor 2α (eIF2α), and thus selective translation of key transcription factors such as activating transcription factor 4 (ATF-4). (2) Increased expression of ER-folding proteins by downstream signalling regulated by activating transcription factor 6 (ATF-6) and by inositol-requiring enzyme 1 (IRE1).
(3) Increased protein degradation to remove misfolded proteins, by the upregulation of the ER-associated protein degradation (ERAD) machinery, through IRE1.
The ultimate function of acute UPR is to enhance the capacity of the ER for protein folding, that is, once the production capacity meets demand and misfolded proteins are removed, UPR is deactivated and normal proteostasis is resumed (Chakrabarti et al., 2011) . However, under conditions of chronic cellular stress, a sustained UPR activation ultimately results in maladaptation and enters a pathological phase. This is signalled by the activation of Jun-N-kinase (JNK), downstream of IRE1, and the selective translation of the proapoptotic mediator CCAAT enhancer-binding protein homologous protein (CHOP), promoted by ATF-4 and ATF-6 (Fig. 1) . These secondary UPR mediators converge upon the B-cell lymphoma-2 (Bcl2) protein family, hence differentially regulating their activity to induce autophagy and/or apoptosis (Bassik et al., 2004; Ogata et al., 2006) . The former predicts cell survival by assisting in the degradation of misfolded proteins, whereas the latter results in cell death by caspase activation. In concert, all three UPR arms also act to promote the expression/activation of proinflammatory mediators through the transcription factor activating protein-1 (AP-1) and nuclear factor κB (NF-κB: Garg et al., 2012) . Inflammatory cells recruited to the damaged tissues may further contribute toward cellular dysfunction and apoptosis.
Many connections between UPR and traditional Alzheimer's disease (AD) pathology have emerged recently. This has led to the suggestion that UPR may be a central pathological pathway, and hence offers promising therapeutic targets for a range of neurodegenerative diseases (for an overview, see Fig. 1 ). Molecular pathways of UPR and potential mechanisms of cellular damage promoting AD-relevant pathology. Damaging factors such as age, environment and lifestyle ( ) affect cellular organelles and hence ER protein folding and cellular homeostasis. Impairments result in increased misfolded proteins, which accumulate in the ER lumen. These sequester protein chaperones such as BIP and lead to the activation of three UPR-arms through PERK, IRE1 and ATF-6. The initially adaptive phase of UPR requires phosphorylation of eIF2α, halting general protein translation, while favouring the translation of protective stress proteins. In parallel, IRE1 activates XBP-1 alongside the cleavage and activation of ATF-6, which together promote the expression of key ER protein chaperones and enhance the ER protein-degrading machinery (ERAD) to clear misfolded proteins. If this adaptive response can restore ER functionality, the stress response is terminated. However, if the protein-handling capacity of the ER remains impaired and UPR persists, it enters a pathological phase: the prolonged blockade of protein translation prevents structural changes essential for plasticity: it increases amyloidogenic processing through BACE1 and PS1, alongside APP trafficking proteins as well as the induction of the proapoptotic mediator CHOP, which in turn increases the expression of proapoptotic Bcl2 proteins. Supported by the activation of JNK stress kinase and GSK3, Bcl2 proteins cause mitochondrial damage as well as autophagy. In conjunction with elevated levels of JNK as well as GSK3, IRE1-mediated degradation of anti-inflammatory factors leads to the upregulation of AP-1/NFkB, promoting the production of chemokines and cytokines and hence inflammation. The continued alteration of Ca 2 + -binding chaperones impairs Ca 2 + homeostasis; this promotes tau phosphorylation and further impairs binding of newly translated proteins. Kinases (JNK/ GSK3) activated downstream from the IRE1 kinase domain. For abbreviations, see text.
Alzheimer's disease pathology and the UPR Koss and Platt 163
UPR and neurodegeneration
Neurodegenerative disorders are also classed as 'proteinopathies', immediately recognizing the central relevance of ER-related and UPR-related functions. Moreover, the vast majority of neurodegenerative cases are idiopathic, which suggests a major impact of age, environment and lifestyle factors. Over the last decade or so, a number of post-mortem investigations have identified elevated UPR markers as present in the tissue most severely affected as a result of various neurodegenerative diseases, including AD (Hoozemans et al., 2005 (Hoozemans et al., , 2009 , tauopathies (Nijholt et al., 2012 ), Parkinson's disease (Hoozemans et al., 2007) , Lewy body dementia (Baek et al., 2016) and amyotrophic lateral sclerosis (ALS: Atkin et al., 2008 ; for a recent overview, see Scheper and Hoozemans, 2015) .
Specific to AD, investigations have centred on the hippocampus and have shown an increase in several key markers of UPR, such as BIP, phosphorylated (p-)PERK, p-IRE and p-eIF2α (Hoozemans et al., 2005 (Hoozemans et al., , 2009 Unterberger et al., 2006) . Immunohistological investigations frequently report a close association of elevated UPR markers and neurons containing pretangle phosphotau pathology. The correlation between the presence of tau pathology and ER stress is further corroborated by neuropathological investigations into tauopathy cases (Nijholt et al., 2012) and from mixed-dementia cases where tau as well as α-synuclein may cause an additive burden (Baek et al., 2016) . Despite this evidence, several studies have failed to find conclusive evidence for the induction of UPR across affected brain regions. Notably, a decrease in total and phosphorylated PERK and eIF2α has been detected despite the upregulation of downstream mediators such as ATF-4, CHOP and the proapoptotic Bcl2-associated X (BAX) protein in human AD cases (de la Monte et al., 2012) . Overall, the evidence appears weaker in temporal and frontal cortices than the robust detection of these UPR mediators in the hippocampus (de la Monte et al., 2012; Baek et al., 2016) . Critically, it must be considered that many negative findings stem from lysed tissues and thus prominent activation of signalling cascades restricted to specific neuronal populations may be masked. Equally, given that these principal activators of UPR are dependent on protein phosphorylation, post-mortem dephosphorylation of substrates must be considered a factor.
PERK
The most widely studied arm of the UPR response is the PERK-eIF2α axis. This key component is central to and overlaps with the 'integrated stress response (ISR)', which is triggered by a wide range of cellular stressors. eIF2α phosphorylation regulates protein translation, cell survival and apoptosis by stress-responsive kinases. So far, these kinases comprise PERK, PKR, general control nondepressible-2 (GCN2) and heme-regulated inhibitor.
All are regulated by dimerization and autophosphorylation; however, signal specificities arise because of each kinase having differing sensitivities to varying cellular stressors, differential subcellular locations and additional substrates beyond eIF2α. Although hemeregulated inhibitor is restricted to cells of the erythroid cell linage and reactive to iron deficiency, PERK, PKR and GCN2 are widely expressed and prominent within the central nervous system. PERK is the principal kinase for eIF2α phosphorylation in response to ER stress, and yet, PKR activation also occurs in response to inflammatory, oxidative and ER stress as well as viral infection. Similarly, GCN2 shows overlapping activation stimuli and responds towards viral infection, amino acid and glucose depletion, as well as ultraviolet irradiation (Donnelly et al., 2013) .
The rate-limiting step in de-novo protein synthesis is translational initiation by presentation of Met-tRNA Met by the eIF2 complex to the ribosomes. This association of Met-tRNA MET with eIF2 is regulated by the binding of GTP, which, after hydrolysis to GDP, requires replacement with GTP by the nucleotide exchange factor eIF2B. The phosphorylation of eIF2α at Ser 51 induced by ISR kinases effectively inhibits the association of eIF2B, preventing GTP exchange. Thus, the levels of eIF2α bound to GTP required for the presentation of Met-tRNA MET decrease, effectively preventing ribosomes from initiating translation [reviewed by Donnelly et al. (2013) ]. Even though overall translation is markedly reduced as a consequence, translation of mRNA with inhibitory upstream open reading frames is paradoxically increased as altered ribosomal engagement can bypass this region, promoting their translation. It is by this mechanism that ER stress and thus eIF2α phosphorylation can lead to increased expression of activating transcription factors such as ATF-4 and consequently CHOP (Vattem and Wek, 2004; Palam et al., 2011) .
Of notable relevance for AD is the enhanced expression of ATF-4 and CHOP, but also β-secretase (BACE1), all derived from mRNA-containing inhibitory open reading frames (Lammich et al., 2004; Zhou and Song, 2006) . As BACE1 is the rate-limiting secretase for the cleavage of amyloid precursor protein (APP), several studies have shown that eIF2α phosphorylation, induced either by PERK (O'Connor et al., 2008) or PKR (Mouton-Liger et al., 2012), can ultimately facilitate BACE expression and thus amyloid β (Aβ) production. Recent work suggests a further mechanism of eIF2α phosphorylation to modulate Aβ production as ATF-4 regulates both BACE1 as well as α-secretase/ADAM10 (Reinhardt et al., 2014) . However, the overall impact of such regulations remains to be fully determined.
In addition to the modulation of Aβ production, the PERK-eIF2α axis is critically involved in the regulation of synaptic plasticity, and thus mechanisms involved in memory formation, likely by direct actions as opposed to actions downstream from Aβ production. Protein translation is required for memory formation and recent evidence has highlighted eIF2α as the limiting factor. Hence, the prolonged phosphorylation of eIF2α could essentially deny neurons the de-novo proteins required for structural adaptations such as synaptic remodelling, essential for learning and memory. Indeed, wild-type mice treated acutely with a p-eIF2α inhibitor [integrated stress response inhibitor (ISRIB); see below for more details] showed enhanced memory performance in both hippocampus-dependent and hippocampus-independent learning tasks (Sidrauski et al., 2013) , and the transient inhibition of PERK was associated with enhanced cortexdependent taste learning (Ounallah-Saad et al., 2014) . Interestingly, despite the superior performance of genetically deficient PERK mice in behavioural tasks that require protein synthesis for learning, such mice showed reduced working memory in several tasks known to be independent of protein synthesis. The latter may indicate an additional role of PERK in the regulation of Ca 2 + dynamics (Zhu et al., 2016) . Nevertheless, the regulation of protein synthesis-dependent memory by p-eIF2α is likely to be multifaceted as ATF-4 (aka CREB-2) is widely accepted to be a repressor of cAMPresponsive element (CREB)-mediated gene expression, required for the conversion of short-term into long-term memory (Kida and Serita, 2014) . Although a variety of consequences for memory and long-term potentiation have been observed following inhibition of each of the eIF2α kinases (Trinh and Klann, 2013) , Aβ-mediated inhibition of LTP in hippocampal slices was dependent on PERK. Conversely, the deletion of PERK prevented the elevation of p-eIF2α levels, inhibition of protein translation and memory deficits in a variety of behavioural paradigms in a familial AD (APPswe/PS1ΔE9) mouse model . Similar results have been observed in 5 × FAD mice where PERK, but not GCN2 haploinsufficiency, blocked the age-dependent increase in BACE1 expression, alongside memory deficits and cholinergic degeneration Ohno, 2013, 2014) .
Evidence for the direct activation of PERK in response to exogenous Aβ is weak as only aggregated, fibrillar Aβ and not oligomeric Aβ increased PERK phosphorylation (Lee et al., 2010a (Lee et al., , 2010b . However, accumulation of pathological tau reportedly resulted in PERK activation (Abisambra et al., 2013; Radford et al., 2015) . Hence, Aβ may act indirectly by tau pathology, or alternatively by inflammatory stressors such as tumour necrosis factor-α (TNFα), which activates PKR and hence the p-eIF2α mediated inhibition of protein translation. This would also result in the activation of the additional arms of UPR (Lourenco et al., 2013; Clarke et al., 2015) .
IRE1
Distinct from the PERK axis of the UPR, IRE1-mediated pathways are also closely associated with AD pathology. IRE1 is a trans-ER-membrane protein containing both endoribonuclease and serine/theronine kinase domains within the cytoplasmic domain (Tirasophon et al., 1998) . Once unbound from BIP, IRE1 oligomerizes and autophosphorylates, which activates the endoribonuclease domain of IRE1 and generates X-box-protein-1 (XBP-1) mRNA (Yoshida et al., 2001) . At rest, XBP-1 mRNA exists in an unspliced form , that is, the DNA-binding domain and the activation domain are separated by an intronic sequence. The translation of XBP-1u mRNA results in a protein deficient for gene activation, which is degraded rapidly. In contrast, upon activation of IRE1's nuclease activity, the intronic sequence of XBP-1u is excised, inducing a frame shift that allows for full translation of XBP-1s, a competent transcription factor (Yoshida, 2007) .
Although a degree of cell type-specific gene activation has been reported, ∼ 95 core genes are upregulated as a result of XBP-1 splicing, which include ER co-chaperones for BIP, ERDJ4 as well as P58
IPK and modestly BIP itself, but also calrecticulin and calnexin alongside components of ERAD such as ER degradation-enhancing α mannosidaselike protein, but also core UPR mediators such as PERK, ATF-4 and XBP-1 (Lee et al., 2003; Acosta-Alvear et al., 2007) . Together, this profile likely enhances the proteinfolding capacity of the ER and facilitates protein clearance. It may also provide a feedback loop to modulate the ongoing UPR by increasing key UPR mediators, but also by the elevation of P58 IPK , which not only acts as a protein chaperone but is also associated with the inhibition of eIF2α kinases, PERK and PKR (Yan et al., 2002; van Huizen et al., 2003) .
The activation of IRE1 is acutely associated with cell survival, and yet, during sustained ER stress, is linked with apoptosis. In addition to classic ER stress-related transcription, a number of AD-relevant gene transcripts may also be regulated, for example the γ-secretase components presenilin 1 (PS1) and nicastrin as well as APP trafficking proteins and the tau kinase cyclin-dependent kinase 5 (Acosta- Alvear et al., 2007) . However, such observations were based on the ectopic expression of XBP-1s in muscle and secretory cells. In contrast, overexpression of XBP-1 in cells of a neuronal lineage strongly enhanced the expression of ADAM10, which was recapitulated following pharmacological induction of UPR (Reinhardt et al., 2014) .
Across the spectrum of neurodegenerative conditions, the involvement of XBP-1 appears to be inconsistent. Invitro evidence has suggested strong activation by both α-synuclein and Aβ oligomers, and yet XBP-1 appears to be relatively insensitive to other toxic aggregates, for example, prion protein or the familial British dementia amyloid protein (Castillo-Carranza et al., 2012). In mouse models of ALS (Hetz et al., 2009 ) and Huntington's disease (Vidal et al., 2012) , the genetic removal of XBP-1 protected against the onset of disease, whereas increasing XBP-1 expression appeared to be protective against Aβ toxicity in cultured neurons (Casas-Tinto et al., 2011) . This protective potential is supported by observations in both the 5 × FAD and an APP/PS1 AD mouse model, where early, presymptomatic upregulation of spliced XPB-1 coincided with an increased ADAM10 expression, followed by a late-stage collapse of XBP-1 associated with disease progression (Reinhardt et al., 2014) . Again, post-mortem data report either an increase in IRE1-mediated activation of XBP-1 (Lee et al., 2010a (Lee et al., , 2010b , or conversely a decrease in spliced XBP-1 mRNA levels despite a prevalence of increased IRE1 activation (Reinhardt et al., 2014) .
Together, the data imply that prolonged UPR signalling may lead to XBP-1 downregulation. Certainly, downregulation of XBP-1 would mimic the mechanistic consequences of the XBP-1 116C/G polymorphism, which disrupts the XBP-1-binding motif and results in a lower level of transcription (Kakiuchi et al., 2003) . This has been identified recently as an AD risk gene within the Chinese population (Liu et al., 2013) . Similarly, a disruption of XBP-1 signalling may also affect the cellular pathology of familial AD, where PS1 mutations have been observed to downregulate IRE1 signalling (Katayama et al., 1999 (Katayama et al., , 2001 ).
With respect to Aβ-mediated toxicity, the nuclease activity of IRE1 may appear to be neuroprotective. However, IRE1 also interacts with numerous additional substrates through its kinase domain, including TNFassociated factor 2, leading to the activation of the wellestablished stress activated JNK (Urano et al., 2000) . Additional connections between IRE1 and JNK comprise numerous cellular stimuli capable of JNK activation, including inflammatory signalling through TNFα and interleukin-1 (IL-1), oxidative stress, ultraviolet irradiation and growth factor deprivations (Cui et al., 2007) . Various stimuli engage mitogen-activated kinase kinase kinases (MAPKKK), which in turn targets MAPK kinases, specifically MAKK4 and MAKK7, ultimately phosphorylating JNK. This induces nuclear responses (including the canonical c-Jun substrate and nuclear hormone receptors) as well as several cytoplasmic changes in ubiquitination-mediated protein degradation, insulin receptor substrate 1 and Bcl2 proteins (Bogoyevitch and Kobe, 2006) and proinflammatory AP-1 (Garg et al., 2012; see below) . JNK signalling undoubtedly plays important physiological roles, for example, in brain development, synaptic plasticity and neuronal regeneration, but prolonged activation of JNK is prominently associated with apoptosis (Mehan et al., 2011) .
In addition, JNK is capable of phosphorylating tau (Reynolds et al., 1997; Anderton et al., 2001) , but also targets a number of substrates relevant for the Aβ cascade. Upstream from Aβ, APP is an effective substrate of JNK and its phosphorylation at Thr668 effectively promotes amyloidogenic cleavage (Standen et al., 2001; Sclip et al., 2011) , potentially by modulation of intracellular APP trafficking (Triaca et al., 2016) . Downstream signalling links JNK with apoptotic pathways, likely through the modulation of apoptotic Bcl2 proteins (Troy et al., 2001) . Consequently, elevated JNK activation, in particular of the p54 forms, has been linked to the agedependent production of Aβ in murine APP/PS1 (Shoji et al., 2000; Savage et al., 2002) , but also in FTD models (Allen et al., 2002) . As oligomeric Aβ may trigger tau hyperphosphorylation in a JNK-dependent manner (Ma et al., 2009; Zhang et al., 2016a) , JNK emerges as a potential link and common denominator for stress responses activated by both Aβ and tau pathologies. Postmortem studies further support this association, with progression of tau pathology in human AD, that is, high cytoplasmic levels are found in neurofibrillary tanglebearing neurons but also in a considerable number of taupositive neurons without mature aggregates (Pei et al., 2001; Lagalwar et al., 2006) . Corresponding findings have also been observed in cases of human FTD (Lagalwar et al., 2007) .
Recently, IRE1 has also been linked to the activation of another principal tau kinase: glycogen synthase 3β (GSK3β: Kim et al., 2015) . At least, in peripheral tissues the activation of GSK3β by IRE1 has been observed, along with changes in proinflammatory cytokines, IL-1 and XBP-1 splicing, leading to a reduction in TNFα (Kim et al., 2015) . In neuronal cell lines, a similar increase in GSK3 activity has also been reported following pharmacological UPR induction, and yet, this shift in activation was attributed to the selective degradation of inhibited GSK3 as opposed to enhanced tyrosine phosphorylation, in accordance with post-mortem investigation (Nijholt et al., 2012) .
GSK3β has shown a striking efficiency in phosphorylating tau and a close association with AD pathology (Maqbool et al., 2016) . Contributions specifically linked to UPR were identified in neuronal cell lines and primary hippocampal neurons (but not fibroblasts or astrocytes), where GSK3 activation appeared to contribute towards UPR-induced apoptosis, either by caspase-3 activation induced by CHOP (Meares et al., 2011) and/or by the regulation of key ER-resident proteins, γ-taxilin and α nascent polypeptide-associated complex subunit, two proteins that are downregulated in AD (Hotokezaka et al., 2015) . In an APP/PS1 mouse model, GSK3β activation appeared to facilitate UPR-mediated cell death following a series of subthreshold hypoxic events, as well as exacerbating tau phosphorylation . Therefore, both JNK and GSK3β provide mechanistic links between key AD pathologies and UPR.
ATF-6
The third arm of UPR involves ATF-6, an ER-resident transmembrane protein. It is inactive in the BIP-bound form, but following the loss of BIP association is trafficked to the Golgi apparatus, where proteolysis (through site 1 and 2 proteases) activates the protein and enables nuclear transcription of key ER proteins, including chaperones (e.g. BIP, GRP94 and Calreticulin) and ERAD components (Shen et al., 2002) . ATF-6 also regulates enzymes for disulphide-bond formation and those related to the Ca 2 + homeostasis, including the SERCA2 gene (Okada et al., 2002) . Notably, there is some functional redundancy with XBP-1 in relation to BIP, other protein chaperones and ERAD proteins (Lee et al., 2003; Yamamoto et al., 2004) , but also with ATF-4 in relation to the expression of CHOP (Okada et al., 2002) . The ATF-6 pathway is arguably the least investigated in relation to neurodegeneration, with few studies carried out to establish its role in human diseases or engagement of pathological cascades. Nevertheless, at least in Parkinson's disease, the activation of ATF-6 has been shown to be protective, in association with an increased expression of the ERAD machinery (Egawa et al., 2011 ); yet, the deposition of α-synuclein may inhibit ATF-6 activation and ER-Golgi trafficking (Credle et al., 2015) . Despite this protective role, recent work suggests that administration of taurine may protect aged rats from isoflurane-induced hippocampal apoptosis by the reduction of CHOP in an ATF-6-dependent manor (Zhang et al., 2016b) . These contradictory findings highlight the need for increased research into the role of ATF-6 in AD and its pathology.
Secondary AD pathologies
Beyond the primary AD pathologies and their implications for neuronal plasticity, UPR likely plays an additional role in other degenerative processes. ER stress is closely associated with autophagy, inflammation and Ca 2 + dyshomeostasis, each of which is implicated in the exacerbation of AD.
UPR and autophagy
Macroautophagy is heavily implicated in the clearance of toxic protein species, including tau and Aβ (Kim et al., 2011; Salminen et al., 2013) , and yet in AD, key autophagic proteins such as Beclin-1 are progressively reduced, sequestered or cleaved, which correlates with cognitive decline (Pickford et al., 2008; Jaeger and Wyss-Coray, 2010; Ma et al., 2010) . Despite the protective role of autophagy as an outcome of UPR, deregulated autophagic processes in AD may facilitate disease progression and favour apoptosis. Outcomes are dependent on the balance, expression and activity of key Bcl2 proteins, controlled by CHOP (Galehdar et al., 2010) and JNK phosphorylation (Bassik et al., 2004) 
UPR and inflammation
Neuroinflammation is mediated by multiprotein inflammasomes against exogenous pathogens and metabolic byproducts and involves proinflammatory caspases that activate cytokines (e.g. IL-1β, IL-18, and IL-33). At present, the nucleotide-binding oligomerization domainlike receptor family pyrin domain-containing-3 is the best-characterized inflammasome in AD (Pennisi et al., 2016) . Cytokine-expressing and chemokine-expressing microglia surround Aβ plaques and overall levels of these proinflammatory agents are elevated in AD brain tissue (Akiyama et al., 2000) . The recruitment of activated glia by proinflammatory agents is regulated by AP-1 and NF-κB (Glass et al., 2010) . Interestingly, PERK and IRE1 converge to promote the activation of these transcription factors: PERK through the eIF2α-mediated downregulation of the NK-κB inhibitor IκB (Jiang et al., 2003) and IRE1 through the promotion of IκB degradation and activation of AP-1 through JNK phosphorylation (Kaneko et al., 2003; Hu et al., 2006) . Thus, UPR activation has the potential to exacerbate proinflammatory signalling and ultimately immune-driven cellular damage and neuronal death.
UPR, Ca 2 + homeostasis and mitochondrial function
Cellular dysfunctions and impaired homeostatic UPR have wide-ranging consequences on protein translation, but also affect other aspects of cellular physiology such as Ca 2 + homeostasis and mitochondrial ATP production. UPR-mediated adaptations have a clear potential to compromise ER physiology and Ca 2 + homeostasis, for example through altered IP 3 receptor activation (Nutt et al., 2002) , Ca 2 + -binding protein chaperones such as calreticulin and regulatory enzymes, including various kinases and phosphatases such as PTP1B (Agouni et al., 2011) , which we have identified as a key regulator of SOCC (Koss et al., 2013) . Consequently, altered Ca 2 + buffering can increase ER luminal Ca 2 + uptake, facilitate agonist-mediated Ca 2 + release, affect ER-mitochondria tethering and Ca 2 + exchange, and suppress SOCC. These changes are key hallmarks of excitotoxicity and lead to enhanced tau phosphorylation, as reported for example after experimental depletion of ER Ca 2 + stores (Hartigan and Johnson, 1999) . ER stress-induced Ca 2 + dysregulation, as well as changes in Bcl2 proteins (Adams and Cory, 1998) can disrupt mitochondrial activity, leading to the collapse of ATP production and apoptotic processes (Vannuvel et al., 2013) . Recently, 'mitochondrial association membranes' (MAM) have emerged as substrates for ER-mitochondria interactions. MAM are specialized areas for lipid metabolism and Ca 2 + transfer (Paillusson et al., 2016) but also for Aβ production (Schreiner et al., 2015) . Interestingly, several key ER chaperones, including BIP, calreticulin and calnexin are enriched in MAM (Hayashi et al., 2009) . MAMs are reportedly decreased in ALS, Parkinson's disease and TDP-43 variants of frontotemporal dementia (Paillusson et al., 2016) , but evidence from post-mortem studies as well as rodent AD models suggests an actual increase in ER-mitochondria associations (Hedskog et al., 2013) . Similar findings have been reported in fibroblasts isolated from both sporadic and familial AD cases (Area-Gomez et al., 2012) , and nanomolar Aβ concentrations also appeared to promote ER-mitochondria associations as well as Ca 2 + transfer in neuronal cultures (Hedskog et al., 2013) . In addition, chemically induced ER stress led to similar changes, but these were followed by a collapse of ATP production and apoptotic activation (Bravo et al., 2011; Vannuvel et al., 2013) . Clearly, these studies imply that mitochondrial pathology and disrupted Ca 2 + handling lie downstream of the UPR.
Emerging therapeutic targets
The cellular cascades engaged by UPR activation offer numerous molecular sites and pathways for pharmacological intervention. However, the diverse signalling components involved and their upstream/downstream pathways paint a complex picture that presents challenges as a complete mechanistic understanding is at present missing.
Chaperones
A key concern when therapeutically targeting UPR components is that the ER stress response is, at least acutely, protective and essential for normal cellular physiology, and therefore, caution must be exercised when targeting this cascade. One potential strategy is to promote chaperones in support of the capacity of the ER for protein handling (proteostasis) and prevent the induction of chronic UPR, instead of attempting selective downstream inhibition.
In line with this strategy, several avenues have been explored in models of neurodegeneration (Table 1) . However, many compounds exert a range of cellular actions, which makes interpretation of data difficult. It is noteworthy that a recent review suggests that a clearer distinction should be made between genuine endogenous chaperons (such as HSPs) and other chemical chaperones and 'proteostasis promoters' as the actions of the latter compounds are likely indirect (Vega et al., 2016) .
ER chaperones
Drugs promoting the expression of ER-specific HSP chaperones may offer a mode of intervention, but limited candidate molecules are available at present. To date, only one such drug has been identified, that is, BIP inducer X (BIX), identified through a high-throughput BIP reporter assay. BIX [1-(-3,4-dihyrdoxy-phenyl)-2-thiocyanate-ethanone] induces a transient increase in BIP expression at low micromolar concentrations, as well as modest increases in GRP94, calreticulin and also CHOP . The induction of these ER stress components is observed in the absence of PERK or IRE1 activation, and yet appears to be dependent on ATF-6 signalling. It protects against chemically induced ER stress and resultant apoptosis, as well as cerebral infarcts, where notably an overall decrease in CHOP expression was observed Oida et al., 2008) . These results have been largely confirmed in response to NMDA and tunicamycin-induced retinal damage (Inokuchi et al., 2009) . Although in-vivo data indicates a narrow therapeutic window in relation to vessel occlusion-induced cerebral infarct (effective at 3 h but not 6 h after insult: Oida et al., 2010) , such limitations may not be of concern when dealing with a progressive neurodegenerative disorder. There are at present no reports on the potential of BIX to perturb the neuropathology or cognitive decline associated with dementia, although the genetic overexpression of BIP has been proven to be protective in models of Parkinson's disease (Gorbatyuk et al., 2012) .
Several other compounds show potential to induce increased BIP expression, which appears to be linked to the inhibition of histone deacetylates (HDAC). These include the pan-HDAC inhibitor trichostatin A and the class I-specific HDAC inhibitor MS275 (Baumeister et al., 2009) , but also the mood-stabilizing drug valproic acid, which also promotes BIP expression dependent on HDAC inhibition (Wang et al., 1999; Shi et al., 2007) . Mechanistically, these drugs appear to inhibit the endogenous repression of HDAC upon the ER stress response element, in turn promoting BIP expression. Although numerous HDAC inhibitors have been tested in AD models in vivo, and beneficial outcomes have been reported, that is, successful modification of neuropathology and preservation of cognition Bang et al., 2015; Klein et al., 2015) , the modulation of ER stress pathways in these models remains to be determined.
Proteostasis promoters
Two well-described compounds in this category are tauroursodeoxycholic acid (TUDCA), a taurinated form of the endogenous bile acid ursodeoxycholic acid (UDCA), and 4-phenyl butyric acid (PBA). These have long been part of health supplements and traditional medicines, and are currently used for example, in liver and muscle support, or urea cycle disorders, respectively. They are well-established protectants against excess UPR, either when induced pharmacologically (Malo et al., 2010; 2013) or in systemic disease models, such as type 2 diabetes (Ozcan et al., 2006) .
Although commonly referred to as chemical chaperones, it remains unclear whether these two principal compounds behave as such. TUDCA has shown only limited inhibition of protein aggregation. It acted primarily indirectly to enhance the properties of endogenous chaperones, for example, by facilitating antiaggregate capabilities of α-crystallin in retinal lens extracts (Song et al., Table 1 UPR-targeting pharmacological agents Alzheimer's disease pathology and the UPR Koss and Platt 169 Table 1 (continued) Drug categories are listed on the basis of the primary mode of action, and major outcomes reported in vitro and in vivo.
Phosphorylation is indicated by a 'p-' prefix.
Where drugs have been evaluated for protective abilities in disease models/or cellular stress, the description is given in bold.
Aβ, amyloid β , AD, Alzheimer's disease; ATF-4, activating transcription factor 4; BACE1, β secretase; BAX, Bcl2-associated X; Bcl, B-cell lymphoma; BIO, 6-bromoindirubin-3′-oxime; BIP, binding immunoglobulin protein; BIX, BIP inducer X; CHOP, CCAAT enhancer-binding protein homologous protein; eIF2α, eukaryotic initiation factor 2α kinase; ERSRE, endoplasmic reticulum stress response element; GADD34, growth arrest and DNA damage-inducible protein 34; GRP94, glucose-regulated protein 94; GSK3β, glycogen syntheses kinase 3β; HDAC, histone deacetylates; IRE1, inositol-requiring enzyme 1; ISRIB, integrated stress response inhibitor; JNK, Jun-N-kinase; NF-κB, Nuclear factor κB; NR, not reported; PBA, 4-phenyl butyric acid; PERK, PRK-like ER kinase; RYR, ryanodine receptor; TDZD, thiadiazolidinone; TUDCA, tauroursodeoxycholic acid; UPR, unfolded protein response; XBP-1, Xbox protein 1 and 2DG, 2-deoxy-D-glucose.
a Where in-vitro studies have been carried out in primary neuronal cultures as opposed to cell lines.
2011). Equally, TUDCA failed to alter the aggregation of synthetic Aβ 1-42 , despite inhibiting apoptosis induced by similar Aβ application to endothelial cells (Viana et al., 2009) . Given the nature of aggregation assays, these findings are in line with the potential of TUDCA to moderate endogenous protein handling rather that direct interaction with the aggregating proteins, although the exact mechanisms remain to be determined. Somewhat more robustly, PBA directly inhibits aggregation when tested against α-lactalbumin and bovine serum albumin (Kubota et al., 2006) . However, lacking evidence for its ability to inhibit Aβ or indeed tau aggregation, it remains plausible that PBA may regulate AD-relevant protein aggregation, or indeed AD pathology more generally, by other means (see below).
Despite this uncertainty, both TUDCA and PBA have been well-established as neuroprotective agents against synthetic Aβ and in APP/PS1-expressing cell lines and primary cultures (Ramalho et al., 2006; Dionisio et al., 2015; Zhang et al., 2016a) . Although most studies have not specifically investigated alterations in the ER stress machinery, neuroprotection can rather consistently be attributed to the blocking of mitochondria-dependent apoptotic pathways through Bcl2 proteins, the reduction of several caspases and the inhibition of JNK signalling cascades, at least when tested in vitro (for examples and details, see Table 1 ). This is consistent with the involvement of mitochondria in Aβ-induced apoptosis and the recent finding that PBA reduces the expression of CHOP and BIP, as well as tau phosphorylation following Aβ oligomer treatment of PC12 and primary neuronal cultures (Zhang et al., 2016a) .
In accordance with the in-vitro work, several groups have identified an effective reduction in Aβ load, restoration of cognitive function and preservation of neuronal integrity in AD mouse models following various treatment regimes with TUDCA or PBA (Table 1) . Best outcomes were often achieved following presymptomatic treatment. Long-term treatments commonly perturbed Aβ plaque deposition, reduced GSK3β activation along with tau phosphorylation and increased glutamatergic receptor subunit expression as well as maintaining synaptic integrity (Wiley et al., 2011; Ricobaraza et al., 2012) . Similar findings have also been reported recently in an FTD model that expresses an aggregate-prone tau fragment (Bondulich et al., 2016) . In many studies, the amelioration of AD-relevant neuropathology occurred alongside improvements in cognition. Shorter treatments administered postsymptomatically also improved cognition and reduced tau phosphorylation, whereas Aβ profiles were inconsistent. An effective decrease in cortical Aβ plaques following a 6-month TUDCA treatment of APP/PS1 mice was reported when administered before plaque deposition (Nunes et al., 2012; Lo et al., 2013) , and yet, when administered following frontal plaque formation, failed to diminish the load and only reduced the late-stage hippocampal plaque pathology (Dionísio et al., 2015) . Similarly, treatment of aged Tg2576 mice with PBA did not reduce plaque load and even Aβ production; yet, cognition and synaptic integrity improved along with a decreased tau phosphorylation (Ricobaraza et al., 2009) .
Therefore, proteostasis promoters may fail to aid plaque clearance and only prevent plaque formation. This is also supported by the reduced neuronal loss observed in hAPP WT overexpressing mice in the absence of plaques and Aβ overproduction (Cuadrado-Tejedor et al., 2013) , which is indicative of alternative mechanisms of action such as the noted HDAC inhibition activity (Kubota et al., 2006) . However, comparative studies with PBA and other HDAC inhibitors that do not affect the ER's chaperone system have shown selective effects of PBA, both for ER stress induced neuronal toxicity in vitro (Mimori et al., 2013) and in AD models (Cuadrado-Tejedor et al., 2013) .
PERK and eIF2α inhibitors
Despite the evidence provided by genetic manipulation of PERK or its immediate downstream substrate eIF2α in models of AD, there are surprisingly few studies utilizing pharmacological inhibitors of PERK (Table 1) . Two such compounds are GSK2606414 (Axten et al., 2012) and the inhibitor of the downstream targets of eIF2α, the so-called ISRIB (Sidrauski et al., 2013) . In vitro, GSK2606414 was effective in inhibiting UPRmediated tau phosphorylation in SH-SY5Y cells (van der Harg et al., 2014) and has shown a dose-dependent inhibition of p-eIF2α activation without altered CHOP or ATF-4 levels in isolated astrocytes, leading to a decrease in the expression of proinflammatory cytokines (Guthrie et al., 2016) . Currently, there are no reports of this neuroprotective potential of GSK2606414 following either AD gene expression or Aβ challenge. GSK2606414 has only been tested in prion and tauopathy models and although a promising reduction of neuronal loss, decreased tau phosphorylation and GSK3β expression were reported, cognitive performance was not assessed . Upon its initial use in vivo, GSK2606414 showed impressive neuroprotective properties, markedly reducing any neurodegeneration in response to prion protein inoculation and considerably reducing attrition rates. However, systemic inhibition of PERK caused pancreatic toxicity, leading to weight loss and high attrition rates, which has severely limited the drug's therapeutic potential (Moreno et al., 2013) . More recently, a follow-up study using ISRIB, which appears devoid of pancreatic toxicity, achieved similar degrees of neuroprotection against prion protein inoculation. ISRIB reportedly acts by an as yet unresolved mechanism that inhibits downstream signalling of eIF2α, partially restoring protein translation without altering eIF2α phosphorylation levels . Although examination of pancreatic tissue has shown no signs of toxicity or tissue loss, significant weight loss was still apparent, the cause of which remains to be determined. Currently, no reports have emerged on the use of ISRIB within AD or FTD models.
IRE1 modulators
Few small molecule modulators of IRE1 have been developed thus far. The best characterized is 4-methylumbelliferone 8-carbaldehyde, which targets and inhibits the endoribonuclease function of IRE1 (Cross et al., 2012) in a manner similar to STF-083010 (Papandreou et al., 2011) ; hence, such drugs fail to address the potentially decreased XBP-1 splicing in AD. Equally, several other compounds identified as IRE1α modulators block XBP-1 splicing while actually increasing IRE1 kinase activation and thus autophosphorylation (Volkmann et al., 2011) . Thus, the dual functional domains of IRE1 in AD and the apparently divergent kinase activation (increased) and endoribonuclease function (reduced) mean that pharmacological targeting of this enzyme is at present problematic.
Despite these issues, some progress towards pharmacological manipulations specific for one functional domain of IRE1 have been made. A comparative study of novel compounds related to PBA (see above) has shown potent inhibition of both kinase and endoribonuclease functions of IRE1, as well as the ATF-6 pathway, which may be independent from HDAC (Zhang et al., 2013) . However, further structural refinement may be needed to offer specific inhibition of the kinase function of IRE1 as some analogues favoured the inhibition of JNK over XBP-1 splicing (Zhang et al., 2013) . Indeed, genetic manipulation of the IRE1 kinase domain can produce a kinasedead IRE1 variant, which still maintained intact RNase functionality (Rubio et al., 2011) . This work essentially showed that the two functional domains can operate in isolation, and thus the selective targeting of each is theoretically possibly. Targeting the RNase domain while inhibiting/blocking the kinase activity may be possible, although no such reports exist for mammalian cells (Korennykh et al., 2009; Wiseman et al., 2010) . Also, the activation of the IRE1 kinase domain may be required for UPR deactivation; therefore, kinase-dead IRE1 variants may be more vulnerable to ER stress. Nevertheless, several small molecule activators of IRE1 RNase activity have now been developed, but cell toxicity remains an issue (Mendez et al., 2015) . Interestingly, a significant reduction in toxicity could be achieved by coadministration of the PERK inhibitor GSK2606414.
Ultimately, the complexity of targeting IRE1 directly suggests that selective inhibition of downstream effector kinases involved in the propagation of the apoptotic cascade may be a more promising approach to interrupt chronic UPR and establish protection.
JNK
In comparison with many of the other UPR-related targets, there have been more thorough investigations into the development of effective JNK inhibitors and characterization of the resulting neuroprotective outcomes in multiple models of AD and other neurodegenerative disease (Table 1 ). An excellent review has recently been published covering the subject extensively (Yarza et al., 2016) . Here, particular attention will be paid to the direct ATPcompetitive inhibitor SP600125, which has been investigated in relation to UPR and AD neurodegeneration.
SP600125 has relatively high specificity for JNK1-3 over other related kinases (Han et al., 2001) . A number of studies have shown considerable neuroprotection with SP600125 towards Aβ-mediated apoptosis in vitro (Yao et al., 2005; Bamji-Mirza et al., 2014; Xu et al., 2015) . SP600125, when administered before or in combination with oligomeric Aβ, mediated a number of UPR-relevant signalling pathways, such as the inhibition of Aβ-mediated suppression of antiapoptotic Bcl2 proteins Bcl-XI and Bcl-W (Yao et al., 2005) as well as the prevention of a key downstream apoptotic effector of CHOP, GADD43 (Xu et al., 2015) . Similar protective effects have been observed in vivo following acute application of SP600125, for example, in rats intrahippocampally injected with fibrillary Aβ 1-42 (Ramin et al., 2011; Yenki et al., 2013; Mohammadi et al., 2016) . These studies report preservation of cognitive abilities along with a lower proapoptotic expression ratio between Bcl2 and BAX, decreased caspase expression and reduction of autophagic markers. Unfortunately, no direct quantification of the principal activators of UPR, or its modulation by JNK inhibition, was reported. Similarly, promising effects have been described following chronic SP600125 treatment or the application of the D-JNKI1-inhibiting peptide in AD mouse models, but a direct investigation of UPR aspects remains unexplored (Sclip et al., 2011; Zhou et al.,. 2015) . However, the treatment of a rat model of AD with the ginsenoside Rg1, an extract known to inhibit JNK , led to reduced AD pathology and apoptosis through the downregulation of IRE1 (Mu et al., 2015) .
Other ER/UPR-relevant therapeutics: GSK3 inhibitors and Ca 2 + stabilizers
The central role of GSK3 in tau phosphorylation and Aβ production and its involvement in both sporadic and familial cases originally led to the GSK3 hypothesis of AD (Hooper et al., 2008) . A range of inhibitors (natural, inorganic metal ions, organosynthetic and peptide-like) are available and have been probed in models of AD (reviewed in: King et al., 2014 ; see Table 1 ). Lithium is arguably the best-studied inhibitor, and despite its questionable specificity, was recently acknowledged as offering protection against dementia in adults treated for bipolar disorders (Gerhard et al., 2015) . Indeed, lithium, but also the synthetic inhibitors, alsteropaullone, 1-azakenpaullone, SB216763 and TDZD-8 as well as the GSK3-specific inhibitor peptide L803-mts, inhibits ER stress-mediated apoptosis in several neuronal models of neurodegeneration (Song et al., 2002; Chen et al., 2004; Hiroi et al., 2005; Takadera et al., 2006) . Mechanistically, the protective effect of GSK3β inhibition would appear to be downstream of UPR induction, reducing CHOP expression independent of ATF-4 and leading to a reduction in caspase-3 activation and subsequent apoptosis (Meares et al., 2011) . Notably, the inhibition of GSK3β may also promote neuronal survival through the increased expression of antiapoptotic Bcl2 proteins and BIP (Hiroi et al., 2005) . Despite promising protective outcomes in vitro and in an in-vivo model of acute liver failure , the exploitation of GSK3β inhibitors for the repression of ER stress in AD models remains to be fully investigated.
A Ca 2 + hypothesis of AD has also been proposed (reviewed in Berridge, 2010) , and as outlined before, identifies the crucial role of ER function, mitochondria and UPR in neuronal physiology and homeostatic control. A range of Ca 2 + channel blockers specifically targeting various Ca 2 + permeable channels, including L, P/ N-type voltage-gated channels, and the NMDA receptor have been trialled against neurodegeneration-related excitotoxicity (Nimmrich and Gross, 2012) . It is noteworthy that memantine, currently prescribed for AD patients at moderate to severe stages, has been marketed on the basis of its NMDA receptor antagonistic actions and the suggested prevention of Ca 2 + overload, although it should be noted that its cholinergic properties are likely more crucial to its temporary benefits (Drever et al., 2007) . Nevertheless, further meta-analysis has shown beneficial outcomes following the treatment of AD patients with the L-type Ca 2 + blocker nimodipine (Lopez-Arrieta, Birks, 2002) . In comparison, less work has been carried out evaluating drugs targeting ER Ca 2 + release mechanisms through IP 3 receptors and RyRs, which may more directly target ER Ca 2 + homeostasis and impact on ER stress. Interestingly, the RyR antagonist dantrolene reduced neuronal cell death associated with UPR activation in a model of cerebral artery occlusion (Li et al., 2005) and inhibited UPR induction and subsequent cell death in a model of a rare peripheral amyloidosis (Teixeira et al., 2006) . Similarly, dantrolene reduced Aβ levels, deficits in synaptic plasticity and memory impairments in several AD models (Oules et al., 2012; Chakroborty et al., 2012; Wu et al., 2015) , although varying protective mechanisms were proposed (Del Prete et al., 2014) .
Crucially, changes in energy metabolism and impaired glucose handling because of failing mitochondria are central to ageing, the primary risk factor for all dementias (Bhatti et al., 2016) . Latrepirdine (tradename: Dimebon), an antihistamine repurposed for the treatment of AD and Huntington's disease, showed promise in experimental models and early trials largely linked with mitochondrial actions, but later failed in phase III clinical trials (Bezprozvanny, 2010) . Other attempts to target mitochondria directly are now under way. For example, natural polyphenols such as resveratrol, an antioxidant and anti-inflammatory agent found in grapes and berries, potentially offer some neuroprotection (Ahmed et al., 2016) , whereas other inhibitors of mitochondrial fission are also being developed (Reddy, 2014) , but implications for UPR pathways remain to be confirmed.
Conclusion
Complex signalling pathways related to neuronal homeostasis and proteostasis are currently being unravelled and provide a better understanding of cellular physiology and pathology. Regulatory mechanisms link UPR not only with protein handling but also with Ca 2 + homeostasis and mitochondrial function, metabolics, inflammation, autophagy and synaptic plasticity, and a number of promising therapeutic targets are now emerging. However, comprehensive investigations into these targets are still required and it is essential to identify not just opportunities but also potential pitfalls to avoid failures of future clinical trials.
